Fentanyl Citrate Injection Shortage: Current Availability and Manufacturer Updates
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Fentanyl Citrate Injection, with certain presentations from Fresenius Kabi USA currently unavailable and others remaining in supply.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Fentanyl Citrate.
What's in Shortage
Fentanyl Citrate Injection (Brand Name: FENTANYL CITRATE) is currently listed in a shortage status by the FDA. This medication is categorized for use in Analgesia/Addiction and Pediatric care. The shortage involves specific presentations of the injection dosage form.
Which Manufacturers Are Affected
Fresenius Kabi USA, LLC is the primary manufacturer listed for this shortage. The availability varies by specific product presentation:
- Unavailable: Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11). The manufacturer notes the next release is expected in February 2026.
- Unavailable: Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05). The manufacturer notes the next release is expected in February 2026.
- Available: Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20, 63323-806-01, 63323-806-02, 63323-806-50).
For all presentations, the manufacturer advises checking with wholesalers for current inventory.
Manufacturer Contact Information:
- Fresenius Kabi USA, LLC: 888-386-1300
Why There's a Shortage
The reason for the shortage is officially listed as "Other." No further specific details regarding production delays or supply chain issues were provided in the database.
What Patients Should Do
If you or a family member are prescribed Fentanyl Citrate Injection, please consider the following steps:
- Consult Your Healthcare Provider: Patients should always consult with their doctor or healthcare provider regarding their treatment plan and any potential impact this shortage may have on their care.
- Speak with Your Pharmacist: Pharmacists often have the most up-to-date information on local inventory and can check with various wholesalers.
- Contact the Manufacturer: You may use the contact information provided above to inquire about supply timelines for specific NDCs.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider for all medical decisions and alternative treatment options.
Source
This information is based on the FDA Drug Shortage Database.
Initial Posting Date: 01/01/2012
Last Updated: 02/05/2026
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.